DE69227380T2 - Verfahren zur bestimmung und behandlung von alzheimer-krankheit - Google Patents

Verfahren zur bestimmung und behandlung von alzheimer-krankheit

Info

Publication number
DE69227380T2
DE69227380T2 DE69227380T DE69227380T DE69227380T2 DE 69227380 T2 DE69227380 T2 DE 69227380T2 DE 69227380 T DE69227380 T DE 69227380T DE 69227380 T DE69227380 T DE 69227380T DE 69227380 T2 DE69227380 T2 DE 69227380T2
Authority
DE
Germany
Prior art keywords
determining
alzheimer disease
treating alzheimer
treating
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69227380T
Other languages
English (en)
Other versions
DE69227380D1 (de
DE69227380T3 (de
Inventor
Colin Masters
Ashley Ian Bush
Konrad Beyreuther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69227380(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of DE69227380D1 publication Critical patent/DE69227380D1/de
Publication of DE69227380T2 publication Critical patent/DE69227380T2/de
Application granted granted Critical
Publication of DE69227380T3 publication Critical patent/DE69227380T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
DE69227380T 1991-11-12 1992-11-12 Verfahren zur bestimmung und behandlung von alzheimer-krankheit Expired - Lifetime DE69227380T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU9438/91 1991-11-12
AUPK943891 1991-11-12
AUPL337492 1992-07-08
AU3374/92 1992-07-08
PCT/AU1992/000610 WO1993010459A1 (en) 1991-11-12 1992-11-12 A method for assaying and treating alzheimer's disease

Publications (3)

Publication Number Publication Date
DE69227380D1 DE69227380D1 (de) 1998-11-26
DE69227380T2 true DE69227380T2 (de) 1999-04-08
DE69227380T3 DE69227380T3 (de) 2007-01-11

Family

ID=25644152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227380T Expired - Lifetime DE69227380T3 (de) 1991-11-12 1992-11-12 Verfahren zur bestimmung und behandlung von alzheimer-krankheit

Country Status (7)

Country Link
US (2) US5705401A (de)
EP (1) EP0613560B2 (de)
JP (1) JP3277211B2 (de)
AU (1) AU669493B2 (de)
CA (1) CA2123211C (de)
DE (1) DE69227380T3 (de)
WO (1) WO1993010459A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005037298A1 (de) * 2005-08-08 2007-03-08 Christine Jaschek Verwendung von Kalium-, Magnesium-, Calcium- und Zink-Elektrolyten zur Behandlung des Elementemangel- und Austrocknungssyndroms Alzheimer und anderer Demenzen

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010459A1 (en) * 1991-11-12 1993-05-27 The University Of Melbourne A method for assaying and treating alzheimer's disease
DK1060750T3 (da) * 1993-03-29 2006-01-09 Univ Kingston Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19518845A1 (de) * 1995-05-23 1996-11-28 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Phytinsäure
JPH0925234A (ja) * 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
WO1997009976A2 (en) * 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
IL115465A0 (en) * 1995-09-29 1995-12-31 Yeda Res & Dev Assay for the diagnosis of dementia
AUPN649395A0 (en) * 1995-11-10 1995-12-07 Ramsay Health Care Pty Ltd A method for diagnosing alzheimer's disease
GB9610829D0 (en) 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
CA2264097C (en) * 1996-08-13 2007-11-27 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP1007048A4 (de) * 1997-03-11 2004-09-22 Gen Hospital Corp Identifizierung von mitteln zur behandlung der alzheimerischen krankheit
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
JP2001513558A (ja) 1997-08-21 2001-09-04 パイ・ニュー・ゲロリュマトス・ソシエテ・アノニム アルツハイマー病を治療するためにファンキノンを使用する方法
US5980914A (en) * 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6183981B1 (en) 1998-03-05 2001-02-06 Board Of Regents, The University Of Texas System Diagnostic assay for late-onset Alzheimer's disease
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
EP1140090B1 (de) 1999-01-07 2004-12-22 P.N. Gerolymatos S.A. Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
WO2002005634A2 (en) 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7517868B2 (en) * 2004-07-19 2009-04-14 Ip-6 Research Inc Phytic citrate compounds and process for preparing the same
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
JP5419131B2 (ja) * 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
FI3851447T3 (fi) 2006-10-12 2023-11-15 Bellus Health Inc Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CL2007003793A1 (es) * 2006-12-22 2008-07-25 Genentech Inc Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a l
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
TW201518320A (zh) * 2007-06-12 2015-05-16 Ac Immune Sa 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RS53174B (en) * 2007-10-05 2014-06-30 Genentech Inc. USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE
WO2009048538A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
CA2726118A1 (en) * 2008-06-12 2009-12-17 Anatoly Nikolaev Method for screening for compounds that inhibit neurodegeneration
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
WO2011060246A2 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012027794A2 (en) * 2010-09-01 2012-03-08 The Mental Health Research Institute Of Victoria Method of treatment and agents useful for same
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2012142666A1 (en) * 2011-04-19 2012-10-26 The Mental Health Research Institute Of Victoria Method of modulating amine oxidase activity and agents useful for same
US10709784B2 (en) * 2011-06-08 2020-07-14 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
WO2015006453A2 (en) * 2013-07-09 2015-01-15 Mayo Foundation For Medical Education And Research Pet imaging of zinc transport
EP3039431A4 (de) * 2013-08-27 2017-05-03 CRC for Mental Health Ltd. Verfahren zur identifizierung von biomarkern neurologischer krankheiten und diagnose von neurologischen krankheiten
EP3761783A4 (de) * 2018-02-26 2021-12-15 The Trustees of Columbia University in the City of New York Zinkassoziierte behandlung und diagnose von kachexie

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US4837164A (en) * 1988-04-27 1989-06-06 Bionix Corporation Methods for diagonosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
JPH05507470A (ja) * 1990-04-12 1993-10-28 アクゾ・エヌ・ヴエー Ｍｃａ２８ａ３２によって認識される抗原ｃｔａａ２８ａ３２
CA2079880A1 (en) * 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection and methods of use of protease nexin-2
AU8215391A (en) * 1990-06-29 1992-01-23 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
WO1992003542A1 (en) * 1990-08-17 1992-03-05 Boston University PROTEASES CAUSING ABNORMAL DEGRADATION OF AMYLOID β-PROTEIN PRECURSOR
JPH04126095A (ja) * 1990-09-14 1992-04-27 Asahi Chem Ind Co Ltd 新規モノクローナル抗体及びそれを産生するハイブリドーマ
ATE286971T1 (de) * 1991-01-21 2005-01-15 Elan Pharm Inc Prüfung und modell für alzheimers-krankheit
JPH04252956A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパク質の測定方法、試薬及びキット
JPH04252955A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd 蛋白質の測定方法、試薬及びキット
JPH04252954A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
WO1993010459A1 (en) * 1991-11-12 1993-05-27 The University Of Melbourne A method for assaying and treating alzheimer's disease
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005037298A1 (de) * 2005-08-08 2007-03-08 Christine Jaschek Verwendung von Kalium-, Magnesium-, Calcium- und Zink-Elektrolyten zur Behandlung des Elementemangel- und Austrocknungssyndroms Alzheimer und anderer Demenzen

Also Published As

Publication number Publication date
JPH07503316A (ja) 1995-04-06
WO1993010459A1 (en) 1993-05-27
US20040265847A1 (en) 2004-12-30
EP0613560B1 (de) 1998-10-21
AU2926392A (en) 1993-06-15
US5705401A (en) 1998-01-06
AU669493B2 (en) 1996-06-13
DE69227380D1 (de) 1998-11-26
JP3277211B2 (ja) 2002-04-22
EP0613560A1 (de) 1994-09-07
DE69227380T3 (de) 2007-01-11
CA2123211A1 (en) 1993-05-27
CA2123211C (en) 2008-09-16
EP0613560A4 (de) 1995-05-17
EP0613560B2 (de) 2006-06-21

Similar Documents

Publication Publication Date Title
DE69227380D1 (de) Verfahren zur bestimmung und behandlung von alzheimer-krankheit
ATE230606T1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69838789D1 (de) Verfahren zur behandlung oder prävention der alzheimerischen krankheit
DE696923T1 (de) Verfahren zur behandlung endo-ostealer materialen
DE69112480T2 (de) Verfahren und Vorrichtung zur Behandlung von medizinischen Abfallstoffen.
DE69331469T2 (de) Verfahren zur behandlung von abfällen
DE69218202D1 (de) Verfahren zur behandlung von fluoroaluminosilikatgläsern
DE69222735D1 (de) Zusammensetzung und Verfahren zur Behandlung von Kühlwasser
DE3888205D1 (de) Verfahren zur behandlung von lungenaffektionen und zubereitungen dafür.
DE69123519T2 (de) Verfahren und Vorrichtung zur Bestimmung von Ionen
DE69624116D1 (de) Verfahren zur behandlung von allergischem asthma
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
DE69231592D1 (de) Verfahren und zusammensetzungen zur behandlung von malaria und anderen erkrankungen
DE69228054D1 (de) Orthomolekulares verfahren zur behandlung von sichelzellanämie
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
ATA66096A (de) Verfahren und vorrichtung zur elektrolytischen behandlung von durchlaufendem gut
DE69006509D1 (de) Verfahren zur behandlung von häuten.
DE69429341T2 (de) Verfahren zur behandlung von flüssigkeiten
DE69634207D1 (de) Verfahren zur behandlung von böden und/oder schüttgütern
DE69214139D1 (de) Verfahren zur behandlung von mit feuchtigkeit enthaltenden feinkohlen
ATA21789A (de) Verfahren zur behandlung von abfallstoffen
ATA171489A (de) Verfahren zur behandlung von abfallstoffen
DE69104438D1 (de) Verfahren zur bestimmung von glukose-6-phosphat und zusammensetzung dafür.
ATA315888A (de) Verfahren zur behandlung von abfallstoffen
DE68911922D1 (de) Vorrichtung und verfahren zur behandlung von bodenbelägen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: PRANA BIOTECHNOLOGY LTD., SOUTH MELBOURNE, VICTORI

8366 Restricted maintained after opposition proceedings